Syndax Pharmaceuticals (NASDAQ:SNDX) Lowered to “Sell” Rating by Wall Street Zen

Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other equities research analysts have also recently issued reports on SNDX. Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. UBS Group lifted their target price on shares of Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. JPMorgan Chase & Co. lowered their price target on shares of Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. Stifel Nicolaus set a $45.00 price objective on shares of Syndax Pharmaceuticals in a report on Friday. Finally, BTIG Research reiterated a “buy” rating and issued a $56.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Syndax Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $37.30.

Syndax Pharmaceuticals Price Performance

Syndax Pharmaceuticals stock opened at $21.71 on Friday. The business’s 50 day simple moving average is $20.86 and its 200 day simple moving average is $17.99. Syndax Pharmaceuticals has a 12 month low of $8.58 and a 12 month high of $22.73. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -6.60 and a beta of 0.46. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, March 2nd. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.12). Syndax Pharmaceuticals had a negative net margin of 165.37% and a negative return on equity of 175.50%. The firm had revenue of $68.73 million during the quarter. During the same quarter in the previous year, the firm posted ($1.10) EPS. Syndax Pharmaceuticals’s revenue for the quarter was up 792.6% on a year-over-year basis. Sell-side analysts forecast that Syndax Pharmaceuticals will post -3.72 EPS for the current year.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 17,159 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $360,853.77. Following the completion of the sale, the chief executive officer owned 491,690 shares of the company’s stock, valued at approximately $10,340,240.70. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Keith A. Goldan sold 3,410 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $21.03, for a total value of $71,712.30. Following the sale, the chief financial officer owned 140,429 shares of the company’s stock, valued at approximately $2,953,221.87. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 30,063 shares of company stock valued at $628,332. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of large investors have recently modified their holdings of SNDX. Pallas Capital Advisors LLC grew its position in Syndax Pharmaceuticals by 8.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 10,985 shares of the company’s stock valued at $231,000 after acquiring an additional 875 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Syndax Pharmaceuticals by 26.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock valued at $89,000 after purchasing an additional 893 shares during the last quarter. Schroder Investment Management Group raised its position in Syndax Pharmaceuticals by 1.0% in the 3rd quarter. Schroder Investment Management Group now owns 123,404 shares of the company’s stock worth $1,920,000 after purchasing an additional 1,241 shares during the period. Verition Fund Management LLC raised its position in Syndax Pharmaceuticals by 7.5% in the 4th quarter. Verition Fund Management LLC now owns 18,460 shares of the company’s stock worth $388,000 after purchasing an additional 1,281 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in Syndax Pharmaceuticals by 9.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,562 shares of the company’s stock worth $374,000 after purchasing an additional 1,455 shares during the last quarter.

Trending Headlines about Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Robust commercial revenue — Syndax reported $68.7M in Q425 and $172.4M for FY2025, driven by product sales; Revuforj (revumenib) net revenue was $44.2M in Q4 (up 38% vs Q3) and Niktimvo (axatilimab‑csfr) net revenue was $56.0M in Q4 (up 22% vs Q3). Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue topped expectations and showed large year‑over‑year growth (Q4 revenue up ~792% YoY), which investors may view as validation of the commercialization ramp. Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress: enrollment completed in the Phase 2 IPF trial of axatilimab with topline data expected in 4Q26 — a clear near‑to‑mid‑term catalyst to monitor. Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst consensus remains constructive — the stock carries an average rating of “Moderate Buy,” which may support sentiment but is not a new catalyst by itself. Syndax Pharmaceuticals, Inc. Receives Average Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Company hosted an earnings conference call and published slides; these materials provide additional detail on commercialization cadence and guidance drivers. View Press Release / Slide Deck
• Negative Sentiment: EPS missed estimates — Syndax reported a Q4 loss of $0.78 per share versus consensus around ($0.64)–($0.66), signaling continued losses and pressure on near‑term profitability. Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Profitability metrics remain weak — the company reported a negative net margin and negative return on equity, underscoring that top‑line growth has yet to translate into earnings. Syndax Q4 Earnings Snapshot / Conference Call

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.